ArticleBlood2022
Anticoagulation in hospitalized patients with COVID-19.
Article in Blood, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and Safety of Direct Oral Anticoagulants Compared With Heparin for Preventing Thromboembolism in Hospitalized Patients With COVID-19: A Systematic Review and Meta-Analysis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisPooled it
- Low-molecular-weight heparin for the prevention of clinical worsening in severe non-critically ill COVID-19 patients: a joint analysis of two randomized controlled trials.Internal and emergency medicine · 2024Trial
- Healthcare costs of COVID-19 hospitalization in maintenance hemodialysis patients during the first two pandemic waves in Romania: a retrospective cohort study.Journal of medicine and life · 2026Article
- The immunothrombosis pathway linking pulmonary disease to stroke and neurodegeneration: mechanisms and therapeutic implications.Frontiers in pharmacology · 2026Review
- COVID-19 Infection and Associated Outcomes in Patients with Nontraumatic Intracerebral Hemorrhage: Analysis of National Inpatient Sample 2020-2022.Neurocritical care · 2025Article
- Genetic and Inflammatory Signatures Associated With Worse Prognosis in Hospitalized Patients With Severe SARS-CoV-2 Infection With and Without Diabetes.Journal of medical virology · 2025Article
- Severely Ill COVID-19 Patients May Exhibit Hypercoagulability Despite Escalated Anticoagulation.Journal of clinical medicine · 2025Article
- Article
- Prevalence, Predictors, and Outcomes of Type 2 NSTEMI in Hospitalized Patients With COVID-19.Journal of the American Heart Association · 2024Article
- A Delphi consensus on the management of anticoagulation in the COVID-19 pandemic: the MONACO study.Cardiovascular diagnosis and therapy · 2023Review
- Venous thromboembolism in an Asian COVID-19 cohort across 3 infection waves-a retrospective observational study.Research and practice in thrombosis and haemostasis · 2023Article
- Anticoagulant therapy in COVID-19: A narrative review.Clinical and translational science · 2023Review
- Incidence, Risk Factors and Mortality Associated with Major Bleeding Events in Hospitalized COVID-19 Patients.Life (Basel, Switzerland) · 2023Article
- Nasopharyngeal viral load at admission is not an independent predictor of thromboembolic complications in unvaccinated COVID-19 hospitalized patients.Journal of thrombosis and thrombolysis · 2023Article
- The intensity of anticoagulant dosing in hospitalized patients with COVID-19: An observational, comparative effectiveness study.Journal of hospital medicine · 2023Observational
- Association of longitudinal platelet count trajectory with ICU mortality: A multi-cohort study.Frontiers in immunology · 2022Article
- What's New in Critical Illness and Injury Science? Alteplase for severe coronavirus disease 2019: Not quite ready to clot bust just hypoxemia.International journal of critical illness and injury scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease-19 (COVID-19) includes a thromboinflammatory syndrome that may manifest with microvascular and macrovascular thrombosis. Patients with COVID-19 have a higher incidence of venous thromboembolism than other hospitalized patients. Three randomized control trials suggesting benefit of therapeutic heparin in hospitalized noncritically ill patients with COVID-19 have led to conditional guideline recommendations for this treatment. By contrast, prophylactic-dose heparin is recommended for critically ill patients. Unprecedented collaboration and rapidly funded research have improved care of hospitalized patients with COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.